ArticleNature immunology2019
The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells.
Abstract read
In one paragraph
Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 109 citations in OpenAlex.
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Unconventional role of hydroxymethylglutaryl-CoA synthase 1 in driving pathogenic TScience advances · 2026Article
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- FPR2/ALX stimulation modulates microglia and natural killer cells to restrict autoimmune astrocytopathy.Acta pharmacologica Sinica · 2026Article
- Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis.Apoptosis : an international journal on programmed cell death · 2026Article
- Endoplasmic reticulum stress in antitumor immunity and immunotherapy resistance: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Transcriptional networks weaving natural killer anti-tumor immune response.Molecular cancer · 2026Review
- Innate immune profiling reveals a specific reduction of CD57Frontiers in immunology · 2026Article
- Comparative profiling of MAIT cells across gastrointestinal cancers identifies conserved NK receptor dysregulation and HCC-specific defects in cytotoxicity and XBP1s signaling.Frontiers in immunology · 2026Article
- Research progress on the role and dysregulation of NK cells in anti-tuberculosis immunity.Frontiers in immunology · 2026Review
- Peroxiredoxin 4 as a switch regulating PTEN/AKT axis in alveolar macrophages activation.Signal transduction and targeted therapy · 2025Article
- Natural killer cell-based immunotherapy for cancer.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- Article
- Integration of Graph Neural Networks and multi-omics analysis identify the predictive factor and key gene for immunotherapy response and prognosis of bladder cancer.Journal of translational medicine · 2024Article
- The circUbqln1, regulated by XBP1s, interplays with 14-3-3ζ to inhibit collagen synthesis and promote osteoarthritis by controlling PRODH activity and proline metabolism.Journal of advanced research · 2024Article
- Interleukin 15: A new intermediary in the effects of exercise and training on skeletal muscle and bone function.Journal of cellular and molecular medicine · 2024Review
- cellPLATO - an unsupervised method for identifying cell behaviour in heterogeneous cell trajectory data.Journal of cell science · 2024Article
- Cytotoxic T-lymphocyte antigen 4 and programmed cell death ligand 1 blockade increases the effectiveness of interleukin-15 immunotherapy in a bovine leukemia model.Veterinary world · 2024Article
- Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping.Nature immunology · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Yufeng WangThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Yibo ZhangThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ping YiThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Wenjuan DongThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ansel P NalinThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-5673-0203
Jianying ZhangDivision of Biostatistics, Department of Information Sciences, City of Hope National Medical Center, Duarte, CA, USA.
Zheng ZhuThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Lichao ChenThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Don M BensonThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Bethany L Mundy-BosseThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Aharon G FreudThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Michael A CaligiuriDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Jianhua YuThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. jiayu@coh.org.ORCID http://orcid.org/0000-0002-0326-3223
The Ohio State University · USCity Of Hope National Medical Center · USArmy Medical University · CN
Funding
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MIL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5MElucidation of Human Natural Killer Cell DevelopmentR01CA208353 · NCI · OHIO STATE UNIVERSITY · PI AHARON G FREUD · 2017 to 2026
$4.0MCharacterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK CellsR01CA247550 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2020 to 2024
$2.2MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MEnhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer PreventionR01CA185301 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 2015 to 2019
$1.8MIL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4MNCI NIH HHS L30 CA199447NCI NIH HHS P01 CA163205NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA185301NCI NIH HHS R01 CA208353NCI NIH HHS R01 CA247550NCI NIH HHS R35 CA210087NCI NIH HHS R37 CA068458NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
Abstract
Interleukin 15 (IL-15) is one of the most important cytokines that regulate the biology of natural killer (NK) cells
Indexed as
Cells, CulturedCell SurvivalCytotoxicity, ImmunologicGene Expression RegulationGranzymesHumansInterleukin-15Killer Cells, NaturalPhosphorylationProtein BindingProtein StabilityProto-Oncogene Proteins c-aktSignal TransductionT-bet Transcription FactorT-Box Domain ProteinsUbiquitinationGranzymesInterleukin-15Proto-Oncogene Proteins c-aktT-bet Transcription FactorT-Box Domain ProteinsX-Box Binding Protein 1XBP1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.